Enhanced anti-cancer effect of AMTB hydrochloride via chitosan nanoparticles in pancreatic cancer.

IF 3.4 2区 医学 Q2 ONCOLOGY
Jiefeng Liu, Yujing Gong, Xinyu Zeng, Miao He, Bin He, Wenbin Gao, Yong Gao
{"title":"Enhanced anti-cancer effect of AMTB hydrochloride via chitosan nanoparticles in pancreatic cancer.","authors":"Jiefeng Liu, Yujing Gong, Xinyu Zeng, Miao He, Bin He, Wenbin Gao, Yong Gao","doi":"10.1186/s12885-025-14356-w","DOIUrl":null,"url":null,"abstract":"<p><p>Pancreatic cancer is a malignancy with poor prognosis and high mortality. This study investigated the use of chitosan nanoparticles (CS-NPs) to encapsulate AMTB, a TRPM8 inhibitor, as a novel strategy to enhance therapeutic efficacy in pancreatic cancer. TRPM8 was overexpressed in pancreatic cancer tissues and associated with poor patient prognosis. AMTB inhibited pancreatic cancer cell proliferation, migration, and invasion by suppressing the EMT process and MMP2/9 expression. CS-NPs@AMTB were successfully synthesized, exhibiting excellent drug release profiles and stronger anti-tumor effects than free AMTB. Both AMTB and CS-NPs@AMTB demonstrated favorable biological safety. This is the first study to apply chitosan nanoparticles for AMTB delivery in pancreatic cancer, significantly enhancing its anti-tumor and anti-metastatic effects (ahout 70% reduction in tumor size). These findings suggest that CS-NPs@AMTB might overcome current therapeutic limitations by improving drug efficacy and targeting metastasis in pancreatic cancer. With further validation through preclinical and clinical studies, this nanoparticle-based delivery strategy holds promise for integration into future therapeutic regimens and personalized treatment approaches.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"944"},"PeriodicalIF":3.4000,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12105253/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12885-025-14356-w","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Pancreatic cancer is a malignancy with poor prognosis and high mortality. This study investigated the use of chitosan nanoparticles (CS-NPs) to encapsulate AMTB, a TRPM8 inhibitor, as a novel strategy to enhance therapeutic efficacy in pancreatic cancer. TRPM8 was overexpressed in pancreatic cancer tissues and associated with poor patient prognosis. AMTB inhibited pancreatic cancer cell proliferation, migration, and invasion by suppressing the EMT process and MMP2/9 expression. CS-NPs@AMTB were successfully synthesized, exhibiting excellent drug release profiles and stronger anti-tumor effects than free AMTB. Both AMTB and CS-NPs@AMTB demonstrated favorable biological safety. This is the first study to apply chitosan nanoparticles for AMTB delivery in pancreatic cancer, significantly enhancing its anti-tumor and anti-metastatic effects (ahout 70% reduction in tumor size). These findings suggest that CS-NPs@AMTB might overcome current therapeutic limitations by improving drug efficacy and targeting metastasis in pancreatic cancer. With further validation through preclinical and clinical studies, this nanoparticle-based delivery strategy holds promise for integration into future therapeutic regimens and personalized treatment approaches.

壳聚糖纳米颗粒增强盐酸AMTB对胰腺癌的抗癌作用。
胰腺癌是一种预后差、死亡率高的恶性肿瘤。本研究探讨了壳聚糖纳米颗粒(CS-NPs)包封TRPM8抑制剂AMTB作为提高胰腺癌治疗效果的新策略。TRPM8在胰腺癌组织中过表达,与患者预后不良相关。AMTB通过抑制EMT过程和MMP2/9表达抑制胰腺癌细胞的增殖、迁移和侵袭。CS-NPs@AMTB成功合成,具有优异的药物释放谱和比游离AMTB更强的抗肿瘤作用。AMTB和CS-NPs@AMTB均表现出良好的生物安全性。这是首次将壳聚糖纳米颗粒应用于AMTB在胰腺癌中的传递,显著增强了其抗肿瘤和抗转移作用(肿瘤大小减少约70%)。这些发现表明CS-NPs@AMTB可能通过提高药物疗效和靶向胰腺癌转移来克服目前的治疗局限性。通过临床前和临床研究的进一步验证,这种基于纳米颗粒的给药策略有望整合到未来的治疗方案和个性化治疗方法中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BMC Cancer
BMC Cancer 医学-肿瘤学
CiteScore
6.00
自引率
2.60%
发文量
1204
审稿时长
6.8 months
期刊介绍: BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信